COMPANY
Navigator Medicines
Funding and NIH signals
- SEC Form D raise Raised $10M (Form D filed Sep 25, 2026). SEC Form D 0002035715-26-000005 (Sep 25, 2026)
Evidence (1 event)
- Sep 25, 2026 · SEC Form D 0002035715-26-000005
Name of Issuer: Navigator Medicines, Inc.; CIK: 2035715; Address: San Mateo, CA; Submission type: D; Filing date: 2026-09-25; Industry Group: Biotechnology; Date of First Sale: 2026-09-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 10000000; Federal exemptions: 06b
- Sep 25, 2026 · SEC Form D 0002035715-26-000005
Raises and deals from press releases
- Raise Series A · $100M · announced Aug 27, 2024 Company release ↗
Source quote
- Aug 27, 2024 · Company release ↗
“In connection with the transaction, Navigator has closed a $100M Series A financing, co-led by RA Capital Management and Forbion.”
- Aug 27, 2024 · Company release ↗
Timeline
- Trial start Phase 2: A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa source ↗
- Trial start Phase 1: A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults. source ↗
- Raise Series A · $100M source ↗
- Trial start Phase 1: Study of NAV-240 in Healthy Volunteers source ↗
Upcoming milestones
- 2027-09 (ESTIMATED) · Phase 2 · A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa · NCT07384975
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07384975 | A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa | Phase 2 | Recruiting | Jan 5, 2026 | 2027-09 (estimated) |
| NCT06933043 | A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults. | Phase 1 | Completed | May 20, 2025 | Nov 20, 2025 (actual) |
| NCT06181786 | Study of NAV-240 in Healthy Volunteers | Phase 1 | Completed | Nov 22, 2023 | Sep 4, 2024 (actual) |